Arginine Therapy for Pain in Sickle Cell Disease: A Phase‐2 Randomized, Placebo‐Controlled Trial
Morris C, Hatabah D, Korman R, Gillespie S, Bakshi N, Brown L, Harris F, Leake D, Rees C, Khemani K, Vichinsky E, Locke A, Wynn B, Griffiths M, Wilkinson H, Kumari P, Sudmeier L, Shiva S, Dampier C. Arginine Therapy for Pain in Sickle Cell Disease: A Phase‐2 Randomized, Placebo‐Controlled Trial. American Journal Of Hematology 2025, 100: 1119-1131. PMID: 40270092, PMCID: PMC12148696, DOI: 10.1002/ajh.27692.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialPatient-reported outcomesArginine therapyArginine bioavailabilityPain scoresVaso-occlusive pain episodesParenteral opioid useTertiary-care children's hospitalPlasma protein carbonyl levelsDose-dependent increasePost hoc sensitivity analysisOxidative stressSickle cell diseaseMeasures of oxidative stressDecreased oxidative stressOpioid-sparingStandard-dosePlacebo groupPlacebo-ControlledPatient 3Primary endpointLoading-doseOpioid usePain episodesClinical outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply